Though psychiatric illnesses have been associated with increased COVID-19 infection risk, limited information exists about the relationship between ADHD and COVID-19.
Methods:
Using the TriNetX COVID-19 Research Network, we examined the impact of ADHD diagnosis and treatment on COVID-19 infection rates and outcomes.
Results:
ADHD patients had greater risk of COVID-19 (risk ratio (RR) 1.11, 95% CI [1.09, 1.12]). Increased risk was higher in females than males, and highest among Asian and Black patients. Within 60 days after COVID-19 diagnosis, ADHD patients had lower rates of hospitalization (RR 0.91, 95% CI [0.86, 0.96]) and mechanical ventilation (RR 0.69, 95% CI [0.58, 0.83]), and a nonsignificant reduced death rate (RR 0.65, 95% CI [0.42, 1.02]). Patients who recently received ADHD medication had higher rates of COVID-19 (RR 1.13; 95% CI [1.10, 1.15]).
Conclusion:
ADHD poses increased risk for COVID-19, but may reduce risk of severe outcomes. ADHD medications modestly impacted COVID-19 risk.
AghazadehY.PapadopoulosV. (2016). The role of the 14-3-3 protein family in health, disease, and drug development. Drug Discovery Today, 21(2), 278–287.
2.
ArbelY.FialkoffC.KernerA.KernerM. (2021). Can increased recovery rates from Coronavirus be explained by prevalence of ADHD? An analysis at the US statewide level. Journal of Attention Disorders, 25(14), 1951–1954.
3.
AttademoL.BernardiniF. (2021). Are dopamine and serotonin involved in COVID-19 pathophysiology?The European Journal of Psychiatry, 35(1), 62–63.
ClarkA.JitM.Warren-GashC.GuthrieB.WangH. H. X.MercerS. W.SandersonC.McKeeM.TroegerC.OngK. L.ChecchiF.PerelP.JosephS.GibbsH. P.BanerjeeA.EggoR. M.; Centre for the Mathematical Modelling of Infectious Diseases COVID-19 working group. (2020). Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: A modelling study. The Lancet Global Health, 8(8), e1003–e1017.
6.
Coelho-SantosV.CardosoF. L.LeitãoR. A.Fontes-RibeiroC. A.SilvaA. P. (2018). Impact of developmental exposure to methylphenidate on rat brain’s immune privilege and behavior: Control versus ADHD model. Brain, Behavior, and Immunity, 68, 169–182.
7.
CohenH. A.GersteinM.YanivN.RichenbergY.JacobsonE.MartonS.HoshenM.Shkalim ZemerV. (2022). Attention-deficit/hyperactivity disorder as a risk factor for COVID-19 infection. Journal of Attention Disorders, 26(7), 985–990.
8.
CostaF. F.RosárioW. R.Ribeiro FariasA. C.de SouzaR. G.Duarte GondimR. S.BarrosoW. A. (2020). Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies. Diabetes & Metabolic Syndrome, 14(5), 809–814.
9.
Esteller-CucalaP.MacedaI.BørglumA. D.DemontisD.FaraoneS. V.CormandB.LaoO. (2020). Genomic analysis of the natural history of attention-deficit/hyperactivity disorder using Neanderthal and ancient Homo sapiens samples. Scientific Reports, 10(1), 8622.
10.
FadlN.AliE.SalemT. Z. (2021). COVID-19: Risk factors associated with infectivity and severity. Scandinavian Journal of Immunology, 93(6), e13039.
11.
FaraoneS. V. (2018). The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neuroscience and Biobehavioral Reviews, 87, 255–270.
12.
FrakolakiE.KalliampakouK. I.KaimouP.MoraitiM.KolaitisN.BoletiH.KoskinasJ.VassilacopoulouD.VassilakiN. (2019). Emerging role of l-Dopa decarboxylase in Flaviviridae virus infections. Cells, 8(8), E837.
13.
GaoY. D.DingM.DongX.ZhangJ. J.Kursat AzkurA.AzkurD.GanH.SunY. L.FuW.LiW.LiangH. L.CaoY. Y.YanQ.CaoC.GaoH. Y.BrüggenM. C.van de VeenW.SokolowskaM.AkdisM.AkdisC. A. (2021). Risk factors for severe and critically ill COVID-19 patients: A review. Allergy, 76(2), 428–455.
14.
HariyantoT. I.KurniawanA. (2020). Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes & Metabolic Syndrome, 14(5), 1429–1430.
15.
InstanesJ. T.KlungsøyrK.HalmøyA.FasmerO. B.HaavikJ. (2018). Adult ADHD and comorbid somatic disease: A systematic literature review. Journal of Attention Disorders, 22(3), 203–228.
16.
JacobsenK. K.KleppeR.JohanssonS.ZayatsT.HaavikJ. (2015). Epistatic and gene wide effects in YWHA and aromatic amino hydroxylase genes across ADHD and other common neuropsychiatric disorders: Association with YWHAE. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 168(6), 423–432.
17.
KleppeR.MartinezA.DøskelandS. O.HaavikJ. (2011). The 14-3-3 proteins in regulation of cellular metabolism. Seminars in Cell and Developmental Biology, 22(7), 713–719.
18.
LeeS. W.YangJ. M.MoonS. Y.YooI. K.HaE. K.KimS. Y.ParkU. M.ChoiS.LeeS. H.AhnY. M.KimJ. M.KohH. Y.YonD. K. (2020). Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: A nationwide cohort study. The Lancet Psychiatry, 7(12), 1025–1031.
19.
LiangW.GuanW.ChenR.WangW.LiJ.XuK.LiC.AiQ.LuW.LiangH.LiS.HeJ. (2020). Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. The Lancet Oncology, 21(3), 335–337.
20.
LiB.YangJ.ZhaoF.ZhiL.WangX.LiuL.BiZ.ZhaoY. (2020). Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology: official journal of the German Cardiac Society, 109(5), 531–538.
21.
LiuL.NiS. Y.YanW.LuQ. D.ZhaoY. M.XuY. Y.MeiH.ShiL.YuanK.HanY.DengJ. H.SunY. K.MengS. Q.JiangZ. D.ZengN.QueJ. Y.ZhengY. B.YangB. N.GongY. M., . . . LuL. (2021). Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: A systematic review, meta-analysis and call for action. EClinicalMedicine, 40, 101111.
22.
LiuN.TanJ. S.LiuL.WangY.HuaL.QianQ. (2021). Genetic predisposition between COVID-19 and four mental illnesses: A bidirectional, two-sample Mendelian randomization study. Frontiers in Psychiatry, 12, 746276.
23.
MartinsM. R.ReinkeA.PetronilhoF. C.GomesK. M.Dal-PizzolF.QuevedoJ. (2006). Methylphenidate treatment induces oxidative stress in young rat brain. Brain Research, 1078(1), 189–197.
24.
MatsushitaK.DingN.KouM.HuX.ChenM.GaoY.HondaY.ZhaoD.DowdyD.MokY.IshigamiJ.AppelL. J. (2020). The relationship of COVID-19 severity with cardiovascular disease and its traditional risk factors: A systematic review and meta-analysis. Global Heart, 15(1), 64.
25.
MerzonE.ManorI.RotemA.SchneiderT.VinkerS.Golan CohenA.LaudenA.WeizmanA.GreenI. (2021). ADHD as a risk factor for infection with Covid-19. Journal of Attention Disorders, 25(13), 1783–1790.
26.
MerzonE.WeissM. D.CorteseS.RotemA.SchneiderT.CraigS. G.VinkerS.Golan CohenA.GreenI.AshkenaziS.WeizmanA.ManorI. (2022). The association between ADHD and the severity of COVID-19 infection. Journal of Attention Disorders, 26(4), 491–501.
27.
MillichapJ. G. (1997). Encephalitis virus and attention deficit hyperactivity disorder. Journal of the Royal Society of Medicine, 90(12), 709–710.
28.
MpekoulisG.FrakolakiE.TakaS.IoannidisA.VassiliouA. G.KalliampakouK. I.PatasK.KarakasiliotisI.AidinisV.ChatzipanagiotouS.AngelakisE.VassilacopoulouD.VassilakiN. (2021). Alteration of L-dopa decarboxylase expression in SARS-CoV-2 infection and its association with the interferon-inducible ACE2 isoform. PLoS One, 16(6), e0253458.
29.
NatafS. (2020). An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19. Journal of Medical Virology, 92(10), 1743–1744.
30.
NathanK. G.LalS. K. (2020). The multifarious role of 14-3-3 family of proteins in viral replication. Viruses, 12(4), E436.
31.
ObsilováV.SilhanJ.BouraE.TeisingerJ.ObsilT. (2008). 14-3-3 proteins: A family of versatile molecular regulators. Physiological research, 57(Suppl 3), S11–S21.
32.
PablosJ. L.GalindoM.CarmonaL.LledóA.RetuertoM.BlancoR.Gonzalez-GayM. A.Martinez-LopezD.CastrejónI.Alvaro-GraciaJ. M.Fernández FernándezD.Mera-VarelaA.Manrique-ArijaS.Mena VázquezN.Fernandez-NebroA.; RIER Investigators Group. (2020). Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: A multicentric matched cohort study. Annals of the Rheumatic Diseases, 79(12), 1544–1549.
33.
PetersD. J. (2020). Community susceptibility and resiliency to COVID-19 across the rural-urban continuum in the United States. The Journal of Rural Health, 36(3), 446–456.
34.
PetrakisD.MarginăD.TsarouhasK.TekosF.StanM.NikitovicD.KouretasD.SpandidosD. A.TsatsakisA. (2020). Obesity - a risk factor for increased COVID-19 prevalence, severity and lethality (Review). Molecular Medicine Reports, 22(1), 9–19.
35.
PollakY.ShohamR.DayanH.Gabrieli-SeriO.BergerI. (2022). Symptoms of ADHD predict lower adaptation to the COVID-19 outbreak: Financial decline, low adherence to preventive measures, psychological distress, and illness-related negative perceptions. Journal of Attention Disorders, 26, 735–746.
36.
RajkumarR. P. (2022). Is there a relationship between ADHD and COVID-19 prevalence and mortality indices? An analysis of data from 156 countries. Journal of Attention Disorders, 26, 1069–1077.
37.
RizzelloF.CalabreseC.SaliceM.CalandriniL.PriviteraH.MelottiL.PeruzziG.DussiasN.BelluzziA.ScaioliE.DecoratoA.SiniscalchiA.FilipponeE.LauretiS.RottoliM.PoggioliG.GionchettiP. (2021). COVID-19 in IBD: The experience of a single tertiary IBD center. Digestive and Liver Disease, 53(3), 271–276.
38.
SchmitzF.SchererE. B. S.MachadoF. R.da CunhaA. A.TagliariB.NettoC. A.WyseA. T. S. (2012). Methylphenidate induces lipid and protein damage in prefrontal cortex, but not in cerebellum, striatum and hippocampus of juvenile rats. Metabolic Brain Disease, 27(4), 605–612.
39.
SunP.LuX.XuC.SunW.PanB. (2020). Understanding of COVID-19 based on current evidence. Journal of Medical Virology, 92(6), 548–551.
40.
SyK. T. L.HawN. J. L.UyJ. (2020). Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infectious Diseases, 52(12), 902–907.
41.
TaquetM.LucianoS.GeddesJ. R.HarrisonP. J. (2021). Bidirectional associations between COVID-19 and psychiatric disorder: Retrospective cohort studies of 62 354 COVID-19 cases in the USA. The Lancet Psychiatry, 8(2), 130–140.
42.
TuanW. J.BabinskiD. E.RabagoD. P.ZgierskaA. E. (2022). Treatment with stimulants and the risk of COVID-19 complications in adults with ADHD. Brain Research Bulletin, 187, 155–161.
43.
TungH. Y. L.LimtungP. (2020). Mutations in the phosphorylation sites of SARS-CoV-2 encoded nucleocapsid protein and structure model of sequestration by protein 14-3-3. Biochemical and Biophysical Research Communications, 532(1), 134–138.
44.
WangQ.XuR.VolkowN. D. (2021). Increased risk of COVID-19 infection and mortality in people with mental disorders: Analysis from electronic health records in the United States. World Psychiatry, 20(1), 124–130.
45.
“WHO Coronavirus (COVID-19) Dashboard.”World Health Organization. https://covid19.who.int. (September 29, 2022).
46.
WilliamsonE. J.WalkerA. J.BhaskaranK.BaconS.BatesC.MortonC. E.CurtisH. J.MehrkarA.EvansD.InglesbyP.CockburnJ.McDonaldH. I.MacKennaB.TomlinsonL.DouglasI. J.RentschC. T.MathurR.WongA. Y. S.GrieveR., . . . GoldacreB. (2020). Factors associated with COVID-19-related death using OpenSAFELY. Nature, 584(7821), 430–436.
47.
ZhongJ.ShenG.YangH.HuangA.ChenX.DongL.WuB.ZhangA.SuL.HouX.SongS.LiH.ZhouW.ZhouT.HuangQ.ChuA.BraunsteinZ.RaoX.YeC.DongL. (2020). COVID-19 in patients with rheumatic disease in Hubei province, China: A multicentre retrospective observational study. The Lancet. Rheumatology, 2(9), e557–e564.
48.
ZhouR. Y.WangJ. J.SunJ. C.YouY.YingJ. N.HanX. M. (2017). Attention deficit hyperactivity disorder may be a highly inflammation and immune-associated disease (Review). Molecular Medicine Reports, 16(4), 5071–5077.
49.
ZietzM.ZuckerJ.TatonettiN. P. (2020). Associations between blood type and COVID-19 infection, intubation, and death. Nature Communications, 11(1), 5761.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
